Prospectively, interventions targeting the lactate metabolic pathway or lactylation signaling (e.g., LDHA inhibitors, MCT blockers, or lactylation-modulating drugs) represent a promising strategy to restore T-cell effector function, augment immunotherapy responses, and provide new strategic directions for glioma immunotherapy. This evidence concerns the gene SLC16A1 and central nervous system cancer.